168 related articles for article (PubMed ID: 10417034)
1. Low-dose diclofenac, naproxen, and ibuprofen cohort study.
Pérez-Gutthann S; García-Rodríguez LA; Duque-Oliart A; Varas-Lorenzo C
Pharmacotherapy; 1999 Jul; 19(7):854-9. PubMed ID: 10417034
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal tract bleeding associated with naproxen sodium vs ibuprofen.
Strom BL; Schinnar R; Bilker WB; Feldman H; Farrar JT; Carson JL
Arch Intern Med; 1997 Dec 8-22; 157(22):2626-31. PubMed ID: 9531232
[TBL] [Abstract][Full Text] [Related]
3. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
[TBL] [Abstract][Full Text] [Related]
4. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Eversmeyer W; Poland M; DeLapp RE; Jensen CP
Am J Med; 1993 Aug; 95(2A):10S-18S. PubMed ID: 8356997
[TBL] [Abstract][Full Text] [Related]
5. Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study.
Nezvalová-Henriksen K; Spigset O; Nordeng H
BJOG; 2013 Jul; 120(8):948-59. PubMed ID: 23489333
[TBL] [Abstract][Full Text] [Related]
6. Diclofenac use and cardiovascular risks: series of nationwide cohort studies.
Schmidt M; Sørensen HT; Pedersen L
BMJ; 2018 Sep; 362():k3426. PubMed ID: 30181258
[TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding.
Kaufman DW; Kelly JP; Sheehan JE; Laszlo A; Wiholm BE; Alfredsson L; Koff RS; Shapiro S
Clin Pharmacol Ther; 1993 Apr; 53(4):485-94. PubMed ID: 8477566
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
[TBL] [Abstract][Full Text] [Related]
9. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
van Staa TP; Rietbrock S; Setakis E; Leufkens HG
J Intern Med; 2008 Nov; 264(5):481-92. PubMed ID: 18624902
[TBL] [Abstract][Full Text] [Related]
10. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
[TBL] [Abstract][Full Text] [Related]
11. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs.
Biskupiak JE; Brixner DI; Howard K; Oderda GM
J Pain Palliat Care Pharmacother; 2006; 20(3):7-14. PubMed ID: 16931473
[TBL] [Abstract][Full Text] [Related]
13. Use of non-steroidal anti-inflammatory drugs in renal transplant patients: A retrospective study.
Sridharan K; Shah S
Int J Risk Saf Med; 2023; 34(4):379-386. PubMed ID: 37154186
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.
McGettigan P; Henry D
PLoS Med; 2011 Sep; 8(9):e1001098. PubMed ID: 21980265
[TBL] [Abstract][Full Text] [Related]
15. Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
Goldstein JL; Zhao SZ; Burke TA; Palmer R; von Allmen H; Henderson SC
Am J Gastroenterol; 2003 Dec; 98(12):2627-34. PubMed ID: 14687808
[TBL] [Abstract][Full Text] [Related]
16. Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.
Ashworth NL; Peloso PM; Muhajarine N; Stang M
J Rheumatol; 2005 Nov; 32(11):2212-7. PubMed ID: 16265705
[TBL] [Abstract][Full Text] [Related]
17. Naproxen sodium did not lead to substantially more upper gastrointestinal tract bleeding than ibuprofen during short term use as an analgesic.
Hawkey CJ
Gut; 1998 Sep; 43(3):315. PubMed ID: 9863472
[No Abstract] [Full Text] [Related]
18. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis.
Henry D; Lim LL; Garcia Rodriguez LA; Perez Gutthann S; Carson JL; Griffin M; Savage R; Logan R; Moride Y; Hawkey C; Hill S; Fries JT
BMJ; 1996 Jun; 312(7046):1563-6. PubMed ID: 8664664
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
[TBL] [Abstract][Full Text] [Related]
20. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
Prescrire Int; 2016 Jan; 25(167):14-6. PubMed ID: 26942254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
